MK0767 in Type 2 Diabetes (0767-012)

NCT00543556•Merck Sharp & Dohme LLC

Summary

This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.

Eligibility

Age

21 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Type 2 Diabetes Mellitus patients between the ages of 21 and 75 inclusive
•Patient is willing to discontinue current therapy for the duration of the study
•Patient is not a heavy drinker

Exclusion Criteria

•Patient has a history of Type 1 diabetes and/or ketoacidosis
•Patient has severe diabetic retinopathy, or nephropathy, or neuropath
•Patient has has anti-hyperglycemic therapy including insulin, or rosiglitazone and pioglitazone or 2 or more oral agents in combination within 8 weeks prior to visit 1
•Patient has a history of, allergy to, intolerance or hypersensitive to troglitazone, rosiglitazone, or pioglitazone including history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments

Key Dates

Start Date

October 1, 2001

Primary Completion Date

November 1, 2003

Completion Date

November 1, 2003

Last Updated

June 15, 2015

Enrollment

514

ACTUAL participants

Conditions

Type 2 Diabetes Mellitus

Interventions

MK0767

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049

Type 2 Diabetes Mellitus (T2DM)Diabetes Distress

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MK0767 in Type 2 Diabetes (0767-012)

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Achieving Routine Intervention and Screening for Emotional Health

Human Immunodeficiency Virus (HIV) Food Insecurities

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease